FTC announcement: https://www.ftc.gov/news-events/news/press-releases/2024/04/...
Note that this comes following “the Commission’s November challenges led to Kaleo Inc., Impax Labs, GlaxoSmithKline, and Glaxo Group delisting patents in response to the FTC’s warning letters” and subsequently “AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline all announc[ing] commitments to cap inhaler out-of-pocket costs at $35.” This process is precedented with delivering wins.